» Articles » PMID: 35690523

Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Logistic Regression Analysis

Overview
Specialty Radiology
Date 2022 Jun 11
PMID 35690523
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to screen for high-risk factors leading to the early recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) and to construct a prediction model and nomogram. This retrospective study included 108 patients with primary HCC who underwent RFA treatment at the Harbin Medical University Cancer Hospital between January 2018 and June 2019. Four risk factors were screened for using univariate and multivariate logistic regression analyses: number of tumors (hazard ratio [HR] = 14.684, 95% confidence interval [CI]: 1.099-196.215, p = 0.042), neutrophil-to-lymphocyte ratio (NLR) (HR = 2.178, 95% CI: 1.003-4.730, p = 0.049), contrast-enhanced ultrasound (CEUS) performance (HR = 6.482, 95% CI: 1.161-36.184, p = 0.033) and α-fetoprotein (AFP) level (HR = 1.001, 95% CI: 1.000-1.003, p = 0.040). We established a prediction model: Logit(p) = -3.096 + 2.827 × (number of tumors >1 = 1) + 1.851 × (CEUS revealing rapid enhancement of blood flow signal in the arterial phase and clearance in the portal phase = 1) + 1.941 × (NLR >1.55 = 1) + 0.257 × (AFP >32.545 = 1). Through clinical decision curve analysis, the model's threshold was 0.043-0.873, indicating a high clinical value. Patients with a high AFP level, typical CEUS enhancement pattern, multiple tumors and elevated NLR are more likely to relapse early.

Citing Articles

Albumin-Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation.

Lee C, You G, Jo H, Jun C, Cho E, Kim I Cancers (Basel). 2025; 16(24.

PMID: 39766066 PMC: 11674869. DOI: 10.3390/cancers16244167.


Nomogram built based on machine learning to predict recurrence in early-stage hepatocellular carcinoma patients treated with ablation.

Zhang H, Sheng S, Qiao W, Sun Y, Jin R Front Oncol. 2024; 14:1395329.

PMID: 38800405 PMC: 11116608. DOI: 10.3389/fonc.2024.1395329.


Nomograms for Predicting the Risk and Prognosis of Liver Metastases in Pancreatic Cancer: A Population-Based Analysis.

Shi H, Li X, Chen Z, Jiang W, Dong S, He R J Pers Med. 2023; 13(3).

PMID: 36983591 PMC: 10056156. DOI: 10.3390/jpm13030409.